Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotorasib - Amgen

Drug Profile

Sotorasib - Amgen

Alternative Names: AMG-510; LUMAKRAS

Latest Information Update: 15 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Carmot Therapeutics
  • Developer Amgen; REVOLUTION Medicines
  • Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase II Colorectal cancer; Solid tumours

Most Recent Events

  • 14 Sep 2021 Registered for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)
  • 08 Sep 2021 Preregistration for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, South Korea (PO) prior to September 2021
  • 08 Sep 2021 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Turkey, Israel, Singapore (PO) prior to September 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top